Gilead Sciences, Q4

Leerink Partnrs Predicts Gilead Sciences Q1 Earnings
Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report issued on Wednesday, February 12th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of $1.
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participant
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.
Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.72 per share a year ago. These figures are adjusted for non-recurring items.
Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects the full year’s revenue to be around $28.4 billion,
Why Gilead Sciences Stock Is Jumping Today
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
FiercePharma3d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Gilead provides upbeat 2025 forecast, shares rise 4%
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...
Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...
StockStory.org on MSN3d
Why Gilead Sciences (GILD) Stock Is Trading Up Today
What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...